PatientsHCPs
This site is for US Healthcare Professionals only.
Si joint edema icon

Here with you to help reduce inflammation in their sacroiliac joints

In PREVENT, as observed in biologic-naive patients

Improvements in SI joint edema score in nr-axSpA1,2

  • While an MRI is not necessary, it can be used to help confirm an nr-axSpA diagnosis3

SI Joint Edema Improvement As Seen On MRI

In PREVENT, MRI SI joint edema improvement was a prespecified exploratory end point in a subgroup of biologic-naive patients through Year 1. No clinical or statistical conclusions can be drawn.2 

Berlin scoring method

MRI Scored Using Modified Berlin Method

Figure adapted with permission from Krohn M et al. J Rheumatol. 2014;41(3):473-480.4 

  • Inflammation seen on MRI is measured using the Berlin score5

  • Inflammatory changes of the SI joints on MRI could indicate a higher rate of progression6

Mean baseline MRI SI joint edema score: 2.5 (150 mg load group), 2.7 (placebo group). At Week 16, mean baseline MRI SI joint edema score levels were 2.6 and 2.7 (COSENTYX 150 mg load and placebo groups, respectively). At Week 16, mean change from baseline: -1.7, -0.5, respectively.1,7

At Year 1, mean baseline MRI SI joint edema score level was 2.7 (COSENTYX 150 mg group). At Year 1, mean change from baseline was -2.0 (150 mg).1

See the inflammation results in AS, an active disease correlateg,j
See the data
*Limitations apply. Up to a $16,000 annual limit. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. Limitations may apply in MA and CA. For complete Terms and Conditions details, call 1-844-267-3689.

Definitions

MRI, magnetic resonance imaging; nr-axSpA, non-radiographic axial spondyloarthritis; SI, sacroiliac.

References

1. Data on file. CAIN457H2315 Data Analysis Report. Novartis Pharmaceuticals Corp; April 2020.

2. Data on file. CAIN457H2315 Clinical Study Report. Novartis Pharmaceuticals Corp; November 2019.

3. Sieper J, Rudwaleit M. Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis. 2005;64(5):659-663.

4. Krohn M, Braum LS, Sieper J, et al. Erosions and fatty lesions of sacroiliac joints in patients with axial spondyloarthritis: evaluation of different MRI techniques and two scoring methods. J Rheumatol. 2014;41(3):473-480.

5. Weiss PF, Maksymowych WP, Lambert RG, et al. Feasibility and reliability of the Spondyloarthritis Research Consortium of Canada sacroiliac joint inflammation score in children. Arthritis Res Ther. 2018;20(1):56.

6. Protopopov M, Poddubnyy D. Radiographic progression in non-radiographic axial spondyloarthritis. Expert Rev Clin Immunol. 2018;14(6):525-533.

7. Data on file. CAIN457H2315 PREVENT Efficacy data sets. Novartis Pharmaceuticals Corp; June 2020.

8. Deodhar A, Blanco R, Dokoupilová E, et al. Improvement of signs and symptoms of nonradiographic axial spondyloarthritis in patients treated with secukinumab: primary results of a randomized, placebo-controlled phase III study. Arthritis Rheumatol. 2021;73(1):110-120 and Supplementary Material.

9. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.

a. Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021;80(5):582-590.

b. Data on file. CAIN457F2342 (FUTURE 5): 2-Year Interim Report. Novartis Pharmaceuticals Corp; May 2019.

c. Data on file. CAIN457F2342 (FUTURE 5): 2-Year Interim Report PASI 90 and ACR Components data. Novartis Pharmaceuticals Corp; January 2020.

d. Data on file. CAIN457F2342 (FUTURE 5): 2-Year Interim Report mNAPSI and PASI 100 data. Novartis Pharmaceuticals Corp; October 2019.

e. Data on file. CAIN457H2315 Data Analysis Report. Novartis Pharmaceuticals Corp; April 2020.

f. Data on file. CAIN457H2315 Clinical Study Report. Novartis Pharmaceuticals Corp; November 2019.

g. Data on file. CAIN457F2310 Data Analysis Report. Novartis Pharmaceuticals Corp; June 2019.

h. Data on file. CAIN457F2310 (MEASURE 2): Nocturnal Back Pain. Novartis Pharmaceuticals Corp; February 2021.

i. Data on file. CAIN457F2342 (FUTURE 5): Interim Data Analysis Report FACIT-Fatigue data through Week 52. Novartis Pharmaceuticals Corp; April 2019.

j. Poddubnyy DA, Rudwaleit M, Listing J, Braun J, Sieper J. Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis. 2010;69(7):1338-1341.

k. Data on file. CAIN457F2342 Clinical Study Report Interim Analysis-Week 24. Novartis Pharmaceuticals Corp; November 2017.

l. Data on file. CAIN457F2342 (FUTURE 5): 2-Year HAQ-DI biologic-naive data. Novartis Pharmaceuticals Corp; February 2021.

m. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.

n. Data on file. Selected EAIRs MEASURE 2 Year 5. Novartis Pharmaceuticals Corp; January 2020.

o. Nash P, Mease PJ, McInnes IB, et al; on behalf of the FUTURE 3 study group. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3). Arthritis Res Ther. 2018;20(1):47.

p. Data on file. LTD Cosentyx Prescriber and Patient Counts. Novartis Pharmaceuticals Corp; July 2021.

q. Boonen A, Sieper J, van der Heijde D, et al. The burden of non-radiographic axial spondyloarthritis. Semin Arthritis Rheum. 2015;44(5):556-562.